New Delhi: A committee set up by the government on Monday, allayed the fear of people that Covishield and Covaxin increase the risk of blood clotting. The committee submitted its findings after analysing over 400 major adverse reactions reported post-COVID-19 vaccinations.
Member of National Task Force on COVID-19 and advisor to national Adverse Events Following Immunization (AEFI) committee, Dr. NK Arora said that these cases have been analysed and there is no unusual bleeding or clotting manifestations either with Covishield or Covaxin. Of 412 cases, including hospitalisations and deaths, there is no abnormal increase in issues of clotting and bleeding, he reportedly said, News18 reported.
These findings have been submitted to the National Expert Group on Vaccine Administration for COVID-19.
Meanwhile, a large trial in the US and two South American countries of the Oxford-AstraZeneca vaccine demonstrated a 79 percent efficacy rate at preventing symptomatic COVID-19 and 100 per cent effectiveness in stopping severe disease and hospitalisation, the firm said on March 22, News18 reported.
The company said the panel found “no increased risk of thrombosis or events characterised by thrombosis among the 21,583 participants receiving at least one dose of the vaccine. The specific search for cerebral venous sinus thrombosis (CVST), which is an extremely rare blood clot in the brain, found no events in this trial.”
